OTC Markets OTCPK - Delayed Quote USD

BioElectronics Corporation (BIEL)

Compare
0.0003 -0.0001 (-25.00%)
As of November 20 at 2:05 PM EST. Market Open.
Loading Chart for BIEL
DELL
  • Previous Close 0.0004
  • Open 0.0004
  • Bid 0.0002 x --
  • Ask 0.0003 x --
  • Day's Range 0.0003 - 0.0004
  • 52 Week Range 0.0001 - 0.0005
  • Volume 32,995,599
  • Avg. Volume 20,293,361
  • Market Cap (intraday) 7.412M
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

www.bielcorp.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIEL

View More

Performance Overview: BIEL

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIEL
50.00%
S&P 500
23.86%

1-Year Return

BIEL
0.00%
S&P 500
29.91%

3-Year Return

BIEL
76.92%
S&P 500
25.75%

5-Year Return

BIEL
57.14%
S&P 500
90.05%

Compare To: BIEL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIEL

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    7.41M

  • Enterprise Value

    7.41M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -18.01%

  • Return on Assets (ttm)

    -33.67%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.61M

  • Net Income Avi to Common (ttm)

    -289.82k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    925

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -554.29k

Research Analysis: BIEL

View More

Company Insights: BIEL

Research Reports: BIEL

View More

People Also Watch